Interferon-gamma in Ascites Could Be a Predictive Biomarker of Outcome in Ovarian Carcinoma
Overview
Authors
Affiliations
Objective: The ovarian cancer-associated ascites is an ideal material for evaluating the interaction between the host immune system and cancer cells in the tumor micro-environment. The aim of this study was to investigate whether the selected target cytokine expression levels in ascites could serve as an immune biomarker for predicting outcomes in ovarian cancer.
Methods: Eighty-eight specimens of ovarian cancer-associated ascites were evaluated to select the target cytokine by a cytokine profiling kit. The 144 total samples were subsequently analyzed for this target cytokine. The correlation between the target cytokine and clinical characteristics was analyzed.
Results: Interferon-gamma (IFN-γ) was identified as the target cytokine. Higher levels of IFN-γ in the ascites of the tumor micro-environment were associated with advanced disease (p=0.012), higher tumor histological grading (p=0.004), and sub-optimal surgical status (p=0.040). By multivariate analysis, the adjusted hazard ratios (HRs) were 2.74 (95% confidence interval (CI) 1.85-4.05, p<0.001) for disease-free survival (DFS) and 1.72 (95% CI 1.01-2.93, p=0.048) for overall survival (OS) for a 10-fold increase in IFN-γ concentration in the ascites. An inverse dose-response relationship between IFN-γ level and survival was also noted (Ptrend<0.001 for DFS and Ptrend<0.042 for OS).
Conclusions: Patients with ovarian cancer and higher IFN-γ expression levels in cancer-associated ascites will have shorter DFS and OS. IFN-γ levels in the ascites may be a prognostic marker and a potential reference for immunotherapy targeting IFN-γ.
Research progress and treatment status of malignant ascites.
He J, Zhang H Front Oncol. 2024; 14:1390426.
PMID: 39737405 PMC: 11682990. DOI: 10.3389/fonc.2024.1390426.
IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance.
Reddy S, Sadia F, Vancura A, Vancurova I Cancers (Basel). 2024; 16(15).
PMID: 39123403 PMC: 11311860. DOI: 10.3390/cancers16152676.
Jeong M, Yoon Y, Kang Y, Kim C, Nam H, Lee Y Cancers (Basel). 2023; 15(8).
PMID: 37190256 PMC: 10137134. DOI: 10.3390/cancers15082328.
Fahmi M, Pradjatmo H, Astuti I, Nindrea R Asian Pac J Cancer Prev. 2021; 22(2):315-323.
PMID: 33639643 PMC: 8190346. DOI: 10.31557/APJCP.2021.22.2.315.
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites.
den Ouden J, Zaman G, Dylus J, van Doornmalen A, Mulder W, Grobben Y Oncotarget. 2020; 11(49):4570-4581.
PMID: 33346216 PMC: 7733621. DOI: 10.18632/oncotarget.27827.